Provided by Tiger Trade Technology Pte. Ltd.

Galecto Inc.

19.34
+1.578.84%
Post-market: 18.85-0.4900-2.53%17:30 EST
Volume:143.07K
Turnover:2.59M
Market Cap:25.67M
PE:-1.61
High:19.41
Open:16.75
Low:16.70
Close:17.77
52wk High:33.60
52wk Low:2.01
Shares:1.33M
Float Shares:1.29M
Volume Ratio:0.98
T/O Rate:11.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.9901
EPS(LYR):-18.5274
ROE:-109.49%
ROA:-43.54%
PB:3.85
PE(LYR):-1.04

Loading ...

Company Profile

Company Name:
Galecto Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
5
Office Location:
Ole Maaloes Vej 3,Copenhagen N,Copenhagen,Capital Region of Denmark,Denmark
Zip Code:
2200
Fax:
- -
Introduction:
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Directors

Name
Position
Hans T. Schambye
President, Chief Executive Officer and Director
Carl Goldfischer
Director and Chair of the Board
Amit D. Munshi
Director
Chris Cain
Director
Jayson Dallas
Director
Julianne Bruno
Director
Peter Harwin
Director

Shareholders

Name
Position
Hans T. Schambye
President, Chief Executive Officer and Director
Lori Firmani
Interim Chief Financial Officer
Garrett Winslow
General Counsel
Matthew Kronmiller
Executive Vice President of Strategy and Chief Business Officer